Maria Zappala'

List of Publications by Year
in descending order

97 papers	3,416 citations	145106 33 h-index	182931 54 g-index
97 all docs	97 docs citations	97 times ranked	3525 citing authors

#	Article	IF	Citations
1	Dual Inhibition of Parasitic Targets: A Valuable Strategy to Treat Malaria and Neglected Tropical Diseases. Current Medicinal Chemistry, 2022, 29, 2952-2978.	1.2	8
2	Development of isoquinolinone derivatives as immunoproteasome inhibitors. Bioorganic and Medicinal Chemistry Letters, 2022, 55, 128478.	1.0	3
3	Development of novel dipeptide nitriles as inhibitors of rhodesain of Trypanosoma brucei rhodesiense. European Journal of Medicinal Chemistry, 2022, 236, 114328.	2.6	11
4	Synthesis and Cytotoxicity of Diarylpentanoids against Sensitive CCRFâ€CEM and Multidrugâ€Resistant CEM/ADR5000 Leukemia Cells. Chemistry and Biodiversity, 2022, 19, .	1.0	0
5	Development of Reduced Peptide Bond Pseudopeptide Michael Acceptors for the Treatment of Human African Trypanosomiasis. Molecules, 2022, 27, 3765.	1.7	8
6	Development of Urea-Bond-Containing Michael Acceptors as Antitrypanosomal Agents Targeting Rhodesain. ACS Medicinal Chemistry Letters, 2022, 13, 1083-1090.	1.3	9
7	Design and NMR conformational analysis in solution of Î²5i-selective inhibitors of immunoproteasome. Journal of Molecular Structure, 2021, 1230, 129633.	1.8	2
8	Lead Discovery of SARS-CoV-2 Main Protease Inhibitors through Covalent Docking-Based Virtual Screening. Journal of Chemical Information and Modeling, 2021, 61, 2062-2073.	2.5	37
9	Falcipain-2 and Falcipain-3 Inhibitors as Promising Antimalarial Agents. Current Medicinal Chemistry, 2021, 28, 3010-3031.	1.2	14
10	Immunoproteasome and Non-Covalent Inhibition: Exploration by Advanced Molecular Dynamics and Docking Methods. Molecules, 2021, 26, 4046.	1.7	3
11	Drug combination studies of PS-1 and quercetin against rhodesain of Trypanosoma brucei rhodesiense. Natural Product Research, 2021, , 1-5.	1.0	1
12	Exploring the SARS-CoV-2 Proteome in the Search of Potential Inhibitors via Structure-Based Pharmacophore Modeling/Docking Approach. Computation, 2020, 8, 77.	1.0	30
13	Peptidyl Vinyl Ketone Irreversible Inhibitors of Rhodesain: Modifications of the P2 Fragment. ChemMedChem, 2020, 15, 1552-1561.	1.6	17
14	Drug Synergism: Studies of Combination of RK-52 and Curcumin against Rhodesain of Trypanosoma brucei rhodesiense. ACS Medicinal Chemistry Letters, 2020, 11, 806-810.	1.3	8
15	Development of Novel Benzodiazepineâ€Based Peptidomimetics as Inhibitors of Rhodesain from Trypanosoma brucei rhodesiense. ChemMedChem, 2020, 15, 995-1001.	1.6	10
16	Drug combination studies of curcumin and genistein against rhodesain of Trypanosoma brucei rhodesiense. Natural Product Research, 2019, 33, 3577-3581.	1.0	13
17	Non-covalent immunoproteasome inhibitors induce cell cycle arrest in multiple myeloma MM.1R cells. Journal of Enzyme Inhibition and Medicinal Chemistry, 2019, 34, 1307-1313.	2.5	11
18	Optimization Strategy of Novel Peptide-Based Michael Acceptors for the Treatment of Human African Trypanosomiasis. Journal of Medicinal Chemistry, 2019, 62, 10617-10629.	2.9	22

#	Article	IF	Citations
19	Development of Novel Amides as Noncovalent Inhibitors of Immunoproteasomes. ChemMedChem, 2019, 14, 842-852.	1.6	18
20	Immunoproteasome-selective and non-selective inhibitors: A promising approach for the treatment of multiple myeloma. , 2018, 182, 176-192.		76
21	Development of novel N -3-bromoisoxazolin-5-yl substituted 2,3-benzodiazepines as noncompetitive AMPAR antagonists. Bioorganic and Medicinal Chemistry, 2017, 25, 3631-3637.	1.4	18
22	Development of Novel Peptide-Based Michael Acceptors Targeting Rhodesain and Falcipain-2 for the Treatment of Neglected Tropical Diseases (NTDs). Journal of Medicinal Chemistry, 2017, 60, 6911-6923.	2.9	46
23	Immunoproteasome-Selective Inhibitors: A Promising Strategy to Treat Hematologic Malignancies, Autoimmune and Inflammatory Diseases. Current Medicinal Chemistry, 2016, 23, 1217-1238.	1.2	36
24	Identification of noncovalent proteasome inhibitors with high selectivity for chymotrypsin-like activity by a multistep structure-based virtual screening. European Journal of Medicinal Chemistry, 2016, 121, 578-591.	2.6	21
25	Development of novel 1,4-benzodiazepine-based Michael acceptors as antitrypanosomal agents. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 3453-3456.	1.0	23
26	Synthesis and biological evaluation of novel peptidomimetics as rhodesain inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2016, 31, 1184-1191.	2.5	27
27	The Inhibition of Cysteine Proteases Rhodesain and TbCatB: A Valuable Approach to Treat Human African Trypanosomiasis. Mini-Reviews in Medicinal Chemistry, 2016, 16, 1374-1391.	1.1	43
28	NMR conformational analysis in solution of a potent class of cysteine proteases inhibitors. Structural Chemistry, 2015, 26, 943-950.	1.0	10
29	Development of novel dipeptide-like rhodesain inhibitors containing the 3-bromoisoxazoline warhead in a constrained conformation. Bioorganic and Medicinal Chemistry, 2015, 23, 7053-7060.	1.4	28
30	Synthesis and Biological Evaluation of Papainâ€Family Cathepsinâ€...Lâ€Like Cysteine Protease Inhibitors Containing a 1,4â€Benzodiazepine Scaffold as Antiprotozoal Agents. ChemMedChem, 2014, 9, 1817-1825.	1.6	30
31	Peptideâ€Based Proteasome Inhibitors in Anticancer Drug Design. Medicinal Research Reviews, 2014, 34, 1001-1069.	5.0	46
32	NMR characterization and conformational analysis of a potent papain-family cathepsin L-like cysteine protease inhibitor with different behaviour in polar and apolar media. Journal of Molecular Structure, 2014, 1076, 337-343.	1.8	13
33	Optimization of peptidomimetic boronates bearing a P3 bicyclic scaffold as proteasome inhibitors. European Journal of Medicinal Chemistry, 2014, 83, 1-14.	2.6	27
34	Development of Novel Selective Peptidomimetics Containing a Boronic Acid Moiety, Targeting the 20S Proteasome as Anticancer Agents. ChemMedChem, 2014, 9, 1801-1816.	1.6	16
35	Identification of a new series of amides as non-covalent proteasome inhibitors. European Journal of Medicinal Chemistry, 2014, 76, 1-9.	2.6	25
36	Synthesis and biological evaluation of new 2-amino-6-(trifluoromethoxy)benzoxazole derivatives, analogues of riluzole. Medicinal Chemistry Research, 2013, 22, 6089-6095.	1.1	4

#	Article	IF	Citations
37	Development of peptidomimetic boronates as proteasome inhibitors. European Journal of Medicinal Chemistry, 2013, 64, 23-34.	2.6	34
38	Synthesis of benzothiazole derivatives and their biological evaluation as anticancer agents. Medicinal Chemistry Research, 2012, 21, 2644-2651.	1.1	27
39	Synthesis and Molecular Modeling Studies of Derivatives of a Highly Potent Peptidomimetic Vinyl Ester as Falcipainâ€2 Inhibitors. ChemMedChem, 2012, 7, 1594-1600.	1.6	27
40	Development of Novel Peptidomimetics Containing a Vinyl Sulfone Moiety as Proteasome Inhibitors. ChemMedChem, 2011, 6, 1228-1237.	1.6	47
41	Peptidomimetics containing a vinyl ketone warhead as falcipain-2 inhibitors. European Journal of Medicinal Chemistry, 2011, 46, 2058-2065.	2.6	30
42	Falcipainâ€2 inhibitors. Medicinal Research Reviews, 2010, 30, 136-167.	5.0	121
43	Constrained peptidomimetics as antiplasmodial falcipain-2 inhibitors. Bioorganic and Medicinal Chemistry, 2010, 18, 4928-4938.	1.4	31
44	Synthesis of novel peptidomimetics as inhibitors of protozoan cysteine proteases falcipain-2 and rhodesain. European Journal of Medicinal Chemistry, 2010, 45, 3228-3233.	2.6	34
45	Synthesis, Chiral Resolution and Pharmacological Evaluation of a 2,3-Benzodiazepine-Derived Noncompetitive AMPA Receptor Antagonist. ChemMedChem, 2009, 4, 415-420.	1.6	1
46	Novel 2H-isoquinolin-3-ones as antiplasmodial falcipain-2 inhibitors. Bioorganic and Medicinal Chemistry, 2009, 17, 6505-6511.	1.4	28
47	Novel Peptidomimetics Containing a Vinyl Ester Moiety as Highly Potent and Selective Falcipain-2 Inhibitors. Journal of Medicinal Chemistry, 2009, 52, 2157-2160.	2.9	73
48	Nonpeptidic Vinyl and Allyl Phosphonates as Falcipainâ€2 Inhibitors. ChemMedChem, 2008, 3, 1030-1033.	1.6	44
49	Structureâ€“activity study of 2,3-benzodiazepin-4-ones noncompetitive AMPAR antagonists: Identification of the 1-(4-amino-3-methylphenyl)-3,5-dihydro-7,8-ethylenedioxy-4H-2,3-benzodiazepin-4-one as neuroprotective agent. Bioorganic and Medicinal Chemistry, 2008, 16, 2200-2211.	1.4	23
50	Development of Peptidomimetics with a Vinyl Sulfone Warhead as Irreversible Falcipain-2 Inhibitors. Journal of Medicinal Chemistry, 2008, 51, 988-996.	2.9	196
51	Enantioseparation, absolute configuration determination, and anticonvulsant activity of (Â±)-1-(4-aminophenyl)-7,8-methylenedioxy-1,2,3,5-tetrahydro-4H-2,3-benzodiazepin-4-one. Chirality, 2007, 19, 16-21.	1.3	3
52	Novel Peptidomimetic Cysteine Protease Inhibitors as Potential Antimalarial Agents. Journal of Medicinal Chemistry, 2006, 49, 3064-3067.	2.9	71
53	Synthesis, Chiral Resolution, and Enantiopharmacology of a Potent 2,3-Benzodiazepine Derivative as Noncompetitive AMPA Receptor Antagonist. Journal of Medicinal Chemistry, 2006, 49, 575-581.	2.9	35
54	New 7,8-ethylenedioxy-2,3-benzodiazepines as noncompetitive AMPA receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 167-170.	1.0	23

#	Article	IF	Citations
55	Enantioselective recognition of 2,3-benzodiazepin-4-one derivatives with anticonvulsant activity on several polysaccharide chiral stationary phases. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2006, 838, 56-62.	1.2	14
56	Synthesis of Novel 3-(Alkylcarbamoyl)-2-aryl-1,2-dihydro-6,7-(methylenedioxy)-3H-quinazolin-4-ones as Anticonvulsant Agents. Chemistry and Biodiversity, 2006, 3, 304-311.	1.0	4
57	Synthesis of 2-semicarbazonomethyl-4,5-methylenedioxyphenylacetic acids as anticonvulsant agents. Il Farmaco, 2005, 60, 231-235.	0.9	6
58	Pharmacophore-Based Design of HIV-1 Integrase Strand-Transfer Inhibitors. Journal of Medicinal Chemistry, 2005, 48, 7084-7088.	2.9	160
59	Computational Strategies in Discovering Novel Non-nucleoside Inhibitors of HIV-1 RT. Journal of Medicinal Chemistry, 2005, 48, 3433-3437.	2.9	58
60	Synthesis of new 2,3-diaryl-1,3-thiazolidin-4-ones as anti-HIV agents. Il Farmaco, 2004, 59, 33-39.	0.9	69
61	Design of 1-substituted 2-arylmethyl-4,5-methylenedioxybenzene derivatives as antiseizure agents. Bioorganic and Medicinal Chemistry, 2004, 12, 3703-3709.	1.4	10
62	Efficient 3D Database Screening for Novel HIV-1 IN Inhibitors. Journal of Chemical Information and Computer Sciences, 2004, 44, 1450-1455.	2.8	44
63	Synthesis of New Potential HIV-1 Integrase Inhibitors. Heterocycles, 2004, 63, 2727.	0.4	19
64	1-Aryl-6,7-methylenedioxy-3 H -quinazolin-4-ones as anticonvulsant agents. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 4427-4430.	1.0	59
65	Synthesis and anti-HIV activity of 2,3-diaryl-1,3-thiazolidin-4-ones. Il Farmaco, 2003, 58, 115-120.	0.9	62
66	Anti-HIV agents: design and discovery of new potent RT inhibitors. Il Farmaco, 2003, 58, 259-263.	0.9	55
67	Synthesis and cytotoxic activity of 1,3-benzodioxole derivatives. Note II. Il Farmaco, 2003, 58, 351-355.	0.9	19
68	Characterization of the mechanism of anticonvulsant activity for a selected set of putative AMPA receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 443-446.	1.0	17
69	Design, Synthesis, Structureâ^'Activity Relationships, and Molecular Modeling Studies of 2,3-Diaryl-1,3-thiazolidin-4-ones as Potent Anti-HIV Agents. Journal of Medicinal Chemistry, 2002, 45, 5410-5413.	2.9	151
70	A SIMPLE AND EFFICIENT SYNTHESIS OF GYKI 52466 AND GYKI 52895. Synthetic Communications, 2002, 32, 527-533.	1.1	12
71	Design and development of 2,3-benzodiazepine (CFM) noncompetitive AMPA receptor antagonists. Il Farmaco, 2002, 57, 129-134.	0.9	25
72	Synthesis and anti-HIV activity of 2,3-diaryl-1,3-thiazolidin-4-(thi)one derivatives. Il Farmaco, 2002, 57, 747-751.	0.9	75

#	Article	IF	Citations
73	Synthesis and antitumor activity of 1,3-benzodioxole derivatives. Il Farmaco, 2002, 57, 853-859.	0.9	31
74	Synthesis and anti-HIV activity of 1-(2,6-difluorophenyl)-1H,3H-thiazolo[3,4-a]benzimidazole structurally-related 1,2-substituted benzimidazoles. Il Farmaco, 2002, 57, 819-823.	0.9	86
75	Novel Potent AMPA/Kainate Receptor Antagonists:Â Synthesis and Anticonvulsant Activity of a Series of 2-[(4-Alkylsemicarbazono)-(4-amino- phenyl)methyl]-4,5-methylenedioxyphenylacetic Acid Alkyl Esters. Journal of Medicinal Chemistry, 2002, 45, 4433-4442.	2.9	14
76	7-Chloro-1-(2,6-difluorophenyl)-1H,3H-thiazolo[3,4-a]benzimidazole and 1-(2,6-difluorophenyl)-6-methyl-1H,3H-thiazolo[3,4-a]benzimidazole. Acta Crystallographica Section C: Crystal Structure Communications, 2001, 57, 572-574.	0.4	3
77	4,5-Dihydro-7,8-dimethoxy-1-phenyl-3H-2,3-benzodiazepin-4-one. Acta Crystallographica Section C: Crystal Structure Communications, 2001, 57, 1225-1227.	0.4	6
78	Synthesis and anticonvulsant activity of novel and potent 1-aryl-7,8-methylenedioxy-1,2,3,5-tetrahydro-4H-2,3-benzodiazepin-4-ones. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 463-466.	1.0	24
79	Discovery of 2,3-diaryl-1,3-thiazolidin-4-ones as potent anti-HIV-1 agents. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 1793-1796.	1.0	214
80	Synthesis and Antitumour Activity of 1H,3H-Thiazolo[3,4-a]benzimidazole Derivatives. Archiv Der Pharmazie, 2001, 334, 203-208.	2.1	14
81	Synthesis and in vitro antitumour activity evaluation of 1-aryl-1H,3H-thiazolo[4,3-b]quinazolines. European Journal of Medicinal Chemistry, 2000, 35, 1115-1119.	2.6	37
82	Synthesis and Evaluation of Pharmacological and Pharmacokinetic Properties of 11H-[1,2,4]Triazolo[4,5-c][2,3]benzodiazepin-3(2H)-ones. Journal of Medicinal Chemistry, 2000, 43, 4834-4839.	2.9	43
83	Synthesis and Anticonvulsant Activity of Novel and Potent 6,7-Methylenedioxyphthalazin-1(2H)-ones. Journal of Medicinal Chemistry, 2000, 43, 2851-2859.	2.9	193
84	Determination of new 2,3-benzodiazepines in rat plasma using high-performance liquid chromatography with ultraviolet detection. Biomedical Applications, 1999, 731, 207-215.	1.7	9
85	Synthesis and Anticonvulsant Activity of Novel and Potent 2,3-Benzodiazepine AMPA/Kainate Receptor Antagonists. Journal of Medicinal Chemistry, 1999, 42, 4414-4421.	2.9	48
86	Synthesis and anticonvulsant activity of new 2,3-benzodiazepines as AMPA receptor antagonists. Il Farmaco, 1999, 54, 178-187.	0.9	27
87	Anticonvulsant Activity and Plasma Level of 2,3-Benzodiazepin-4-ones (CFMs) in Genetically Epilepsy-Prone Rats. Pharmacology Biochemistry and Behavior, 1999, 63, 621-627.	1.3	18
88	AMPA receptor antagonists. Expert Opinion on Therapeutic Patents, 1999, 9, 557-570.	2.4	44
89	Relationship Between Anticonvulsant Activity and Plasma Level of Some 2,3-Benzodiazepines in Genetically Epilepsy-Prone Rats. Pharmacology Biochemistry and Behavior, 1998, 61, 215-220.	1.3	21
90	7,8-Methylenedioxy-4H-2,3-benzodiazepin-4-ones as novel AMPA receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 1998, 8, 971-976.	1.0	39

#	Article	IF	Citations
91	High-performance liquid chromatographic determination of new 2,3-benzodiazepines. Biomedical Applications, 1998, 705, 149-153.	1.7	15
92	3,5-Dihydro-4H-2,3-benzodiazepine-4-thiones:Â A New Class of AMPA Receptor Antagonists. Journal of Medicinal Chemistry, 1998, 41, 3409-3416.	2.9	44
93	Convulsant effects of some xanthine derivatives in genetically epilepsy-prone rats. Naunyn-Schmiedeberg's Archives of Pharmacology, 1997, 356, 48-55.	1.4	40
94	Synthesis and characterization in solid and solution of trans-dichloro-1-(2â€²,6â€²-difluorophenyl)-1H,3H-thiazolo[3,4-a]-benzimidazole(tri-n-propyl-phosphine)-palladium(II)â€³: A palladium(II) complex of a ligand with anti-HIV properties. Journal of Inorganic Biochemistry, 1997, 65, 97-102.	1.5	5
95	Azirino[1, 2-d][1, 4]benzodiazepine derivatives and related 1,4-benzodiazepines as anticonvulsant agents in DBA/2 mice. General Pharmacology, 1996, 27, 1155-1162.	0.7	6
96	Anticonvulsant activity of pyrrolo[1â€²,2â€²:1,2]imidazo[4,5-b]pyridines, pyrrolo[2â€²,1â€²:2,3]imidazo[4,5-c] pyridines and pyrrolo[2,1-f]purines in DBA/2 mice. General Pharmacology, 1994, 25, 1027-1031.	0.7	8
97	Compounds with potential anti-tumor activity VII. Synthesis and anti-tumor activity of 1-aryl-N,Nâ€²-di(1,3,4-thiadiazol-2-yl)methylenediamines. European Journal of Medicinal Chemistry, 1989, 24, 131-135.	2.6	6